Ascendis Pharma A (ASND) FCF Margin (2014 - 2026)
Ascendis Pharma A (ASND) posted FCF Margin of 3.13% for Q1 2026, up 87.73% sequentially from 25.52% in Q4 2025, and up 1105.0% YoY from 0.26% in Q1 2025.
Powered by 
Analysis
Ascendis Pharma A (ASND) FCF Margin (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported FCF Margin for 13 years, with the latest figure at 3.13% in Q1 2026.
- Quarterly FCF Margin rose 1105.0% year-over-year to 3.13% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.52% (up 3202.0% YoY) and the FY2025 annual result came in at 17.47%, up 5799.0% from the prior year.
- FCF Margin climbed to 3.13% in Q1 2026 per ASND's latest filing, from 25.52% in the prior quarter.
- Over five years, FCF Margin peaked at 1.01% in Q3 2025 and troughed at 1958.88% in Q2 2022.
- A 5-year average of 383.57% and a median of 105.72% in 2024 frame the typical range for FCF Margin.
- The widest YoY moves for FCF Margin: up 896274 bps in 2022, down 40736 bps in 2022.
- Over 5 years, FCF Margin stood at 602.33% in 2022, then soared by 98 bps to 14.05% in 2023, then tumbled by 100 bps to 28.12% in 2024, then climbed by 9 bps to 25.52% in 2025, then jumped by 88 bps to 3.13% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 3.13%, 25.52%, and 1.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Ascendis Pharma A | 16.39 Bn | 15.45 Bn | 362.22 Mn | 83.02% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 83.02% |
| Mar 31, 2026 | -3.13% |
| Dec 31, 2025 | -42.94% |
| Sep 30, 2025 | 1.01% |
| Jun 30, 2025 | -4.64% |
| Mar 31, 2025 | -14.18% |
| Dec 31, 2024 | -50.13% |
| Sep 30, 2024 | -96.25% |
| Jun 30, 2024 | -169.36% |
| Mar 31, 2024 | -105.72% |
| Dec 31, 2023 | -30.89% |
| Sep 30, 2023 | -257.62% |
| Jun 30, 2023 | -322.17% |
| Mar 31, 2023 | -434.54% |
| Dec 31, 2022 | -602.33% |
| Sep 30, 2022 | -625.70% |
| Jun 30, 2022 | -1,958.88% |
| Mar 31, 2022 | -1,859.55% |
| Dec 31, 2021 | -137.60% |
| Sep 30, 2021 | -7,746.54% |